Salt of omecamtiv mecarbil and process for preparing salt
Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.
1. A pharmaceutical composition comprising omecamtiv mecarbil dihydrochloride hydrate salt and a pharmaceutically acceptable excipient.
2. The pharmaceutical composition of claim 1 , wherein the omecamtiv mecarbil dihydrochloride hydrate salt is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.6, 14.9, 20.1, 21.4, and 26.8±0.2° 2 θ using CuKα radiation.
3. The pharmaceutical composition of claim 2 , wherein the X-ray powder diffraction pattern further comprises peaks at 8.4, 24.2, 26.0, and 33.3±0.2° 2 θ using CuKα radiation.
4. The pharmaceutical composition of claim 2 , wherein the X-ray powder diffraction patter further comprises peaks at about 6.2, 9.7, 13.2, 14.3, 15.4, 16.3, 16.9, 18.9, 19.5, 20.7, 21.8, 22.8, 23.6, 25.1, 27.3, 27.7, 28.4, 29.4, 30.2, 31.2, 31.5, 31.9, 33.9, 34.5, 34.9, 36.1, 36.8, 37.7, 38.5, and 39.7±0.2° θ using Cu Kα radiation.
5. The pharmaceutical composition of claim 1 , wherein the omecamtiv mecarbil dihydrochloride hydrate salt has an X-ray powder diffraction pattern substantially as shown in FIG. 2 .
6. The pharmaceutical composition of claim 2 , wherein the omecamtiv mecarbil dihydrochloride hydrate salt has an endothermic transition at about 230° C. to about 240° C., as measured by differential scanning calorimetry.
7. The pharmaceutical composition of claim 6 , wherein the endothermic transition is at about 235° C.
8. The pharmaceutical composition of claim 1 , wherein the omecamtiv mecarbil dihydrochloride hydrate salt is characterized by an X-ray powder diffraction pattern comprising peaks at 6.6, 8.4, 14.9, 15.4, and 26.8±0.2° 2θ using Cu Kα radiation.
9. The pharmaceutical composition of claim 8 , wherein the X-ray powder diffraction pattern further comprises peaks at 16.3, 19.5, 21.8, 22.8, 27.7, and 28.4±0.2° 2θ using Cu Kα radiation.
10. The pharmaceutical composition of claim 8 , wherein the X-ray powder diffraction pattern further comprises peaks at 9.7, 25.1, 27.3, 29.4, 30.2, 31.2, 34.5, and 34.9±0.2° 2θ using Cu Kα radiation.
11. The pharmaceutical composition of claim 1 , wherein the omecamtiv mecarbil dihydrochloride hydrate salt is characterized by an X-ray powder diffraction pattern comprising peaks at 6.6, 14.9, 16.3, 19.5, and 26.8±0.2° 2θ using Cu Kα radiation.
12. The pharmaceutical composition of claim 11 , wherein the X-ray powder diffraction pattern further comprises peaks at 21.8, 22.8, 27.7, and 28.4±0.2° 2 θ using Cu Kα radiation.
13. The pharmaceutical composition of claim 1 , wherein the omecamtiv mecarbil dihydrochloride hydrate salt is characterized by a single crystal x-ray diffraction (XRD) pattern comprising a triclinic space group of P-1 and unit cell parameters of about a=5.9979(4) {acute over (Å)}, b=13.4375(9) {acute over (Å)}, c=14.4250(9) {acute over (Å)}, α=97.617(4°); β=93.285(4°); and γ=94.585(5°).
14. The pharmaceutical composition of claim 1 , wherein the omecamtiv mecarbil dihydrochloride hydrate salt has an endothermic transition at 230° C. to 240° C., as measured by differential scanning calorimetry.
15. The pharmaceutical composition of claim 14 , wherein the endothermic transition is at 235° C.
16. The pharmaceutical composition of claim 1 , wherein the omecamtiv mecarbil dihydrochloride hydrate salt is characterized by a differential scanning calorimetry (DSC) thermograph as shown in FIG. 5 , when the salt is heated from 25° C. at a rate of 10° C./min.
17. The pharmaceutical composition of claim 1 , wherein the omecamtiv mecarbil dihydrochloride hydrate salt has a dynamic vapor sorption (DVS) profile substantially as shown in FIG. 1 .
18. The pharmaceutical composition of claim 1 , wherein the omecamtiv mecarbil dihydrochloride hydrate salt has a thermogravimetric analysis (TGA) substantially as depicted in FIG. 5 .
19. The pharmaceutical composition of claim 1 , wherein the omecamtiv mecarbil dihydrochloride hydrate salt has a weight loss in a range of 2% to 5% with an onset temperature in a range of 100° C. to 150° C. by thermogravimetric analysis (TGA).
20. The pharmaceutical composition of claim 1 , wherein the omecamtiv mecarbil dihydrochloride hydrate salt has a water solubility of greater than 40 mg/mL at pH 3.5.